HALO - ハロザイム・セラピュ―ティクス (Halozyme Therapeutics Inc.) ハロザイム・セラピュ―ティクス



symbol HALO
会社名 Halozyme Therapeutics Inc (ハロザイム・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ハロザイム・セラピューティクス(Halozyme Therapeutics Inc.)は腫瘍学療法の開発と商業化を行うバイオ医薬品会社である。同社はヒトの酵素および他の候補薬剤の研究、開発、および商業化を行う。同社のセグメントには研究・開発活動およびHylenex組換え品の製品・販売を含む。同社の開発パイプラインは腫瘍学における臨床段階の製品候補を含む。リード腫瘍学プログラムはHAを蓄積する腫瘍の全身治療のために開発された分子実体であるPEGPH20(ポリエチレングリコール(PEG)イル化組換えヒトヒアルロニダーゼ)である。同社はステージIVの膵管腺癌(試験109-202および109-301)におけるPEGPH20の第II相および第III相臨床試験、非小細胞肺癌におけるフェーズIb臨床試験(試験107-201)、および非小細胞肺癌および胃癌におけるフェーズIb臨床試験(試験107-101)にある。   ハロザイム・セラピュ―ティクスは、米国のバイオ医薬品会社。細胞外マトリックスを変更するヒト酵素の研究に基づき、糖尿病、癌、皮膚病治療用の薬品を開発。同社の承認された製品や製品候補は、特許を取得した遺伝子組換え型ヒトヒアルロニダ―ゼ酵素「rHuPH20」をベ―スとしている。主要製品は、「Hylenex」「超高速インスリンプログラム」など。   Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.
本社所在地 11388 Sorrento Valley Road San Diego CA 92121 USA
代表者氏名 Connie L. Matsui コニー・マツイ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 858-794-8889
設立年月日 1998年
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 255人
url www.halozyme.com
nasdaq_url https://www.nasdaq.com/symbol/halo
EBITDA EBITDA(百万ドル) 92.39600
終値(lastsale) 17.53
時価総額(marketcap) 2529653327.2
時価総額 時価総額(百万ドル) 2360.817
売上高 売上高(百万ドル) 319.36900
企業価値(EV) 企業価値(EV)(百万ドル) 2127.968
当期純利益 当期純利益(百万ドル) 76.27700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Halozyme Therapeutics Inc. revenues increased 4% to $66.1M. Net loss decreased 21% to $50.4M. Revenues reflect Royalties increase of 43% to $40.9M Revenues under collaborative agreements increase of 33% to $13.9M. Lower net loss reflects Investment and other income increase from $722K to $3.7M (income) Interest expense decrease of 9% to $10M (expense).



   Halozyme Therapeutics Inc (HALO): Price Now Near $41.71; Daily Chart Shows Downtrend on 50 Day Basis  2021/08/31 15:18:02 ETF Daily News
Of note is that the 50 day changed directions on halo; it is now pointing down. The post Halozyme Therapeutics Inc (HALO): Price Now Near $41.71; Daily Chart Shows Downtrend on 50 Day Basis appeared first on ETF Daily News .
   Halozyme Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/13 22:08:26 Seeking Alpha
   Halozyme Therapeutics Inc (HALO) President and CEO Helen Torley Sold $2.1 million of Shares  2021/08/11 20:15:07 GuruFocus
Related Stocks: HALO ,
   Halozyme Stock Gains As Q2 Earnings Top Estimates On Higher Milestone, Royalty; Lifts FY21 Guidance  2021/08/10 10:51:33 Benzinga
Halozyme Therapeutics Inc (NASDAQ: HALO ) reported Q2 revenue of $136.5 million compared to $55.2 million a year ago, beating the consensus of $103.16 million. The increase was primarily driven by $60.0 million in milestone revenues, including $40 million from ViiV and $20 million from Janssen earned upon achieving Full story available on Benzinga.com
   Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2021 Results - Earnings Call Transcript  2021/08/10 00:47:06 Seeking Alpha
   ViiV Healthcare, Halozyme partner to develop HIV medicines  2021/06/23 12:13:38 Pharmaceutical Business Review
ViiV Healthcare has signed a global collaboration and license agreement with Halozyme Therapeutics to develop ultra-long-acting medicines for HIV. The deal gives exclusive access to Halozymes ENHANZE drug The post ViiV Healthcare, Halozyme partner to develop HIV medicines appeared first on Pharmaceutical Business review .
   Halozyme Collaborates with ViiV Healthcare to Develop Ultra-Long-Acting HIV Meds  2021/06/22 13:05:43 Smarter Analyst
Biopharmaceutical company Halozyme Therapeutics (HALO) has entered into a global collaboration and licensing agreement with ViiV Healthcare to further the development of ultra-long-acting The post Halozyme Collaborates with ViiV Healthcare to Develop Ultra-Long-Acting HIV Meds appeared first on Smarter Analyst .
   Halozyme Therapeutics Inc (HALO) President and CEO Helen Torley Sold $2 million of Shares  2021/06/08 22:15:03 GuruFocus
Related Stocks: HALO ,
   Halozyme to Present at Upcoming Investor Conferences  2021/05/28 20:40:00 PR Newswire
SAN DIEGO, May 28, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it will participate at the following investor conferences: The Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 11:20 a.m. ET / 8:20 a.m. ET. Dr. Helen
   Halozyme Therapeutics Stock Gives Every Indication Of Being Modestly Overvalued  2021/05/20 15:12:03 GuruFocus
Related Stocks: HALO ,

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ハロザイム・セラピュ―ティクス HALO Halozyme Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)